Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

IR-contact

 

 

 

Karl Hård, Head of Investor Relations & Communications
karl.hard@egetis.com Phone: +46 733 011 944

Nicklas Westerholm, CEO
nicklas.westerholm@egetis.com

Yilmaz Mahshid, CFO
yilmaz.mahshid@egetis.com

Calendar and upcoming reports

August 22, 2023
Interim report January-June 2023

November 8, 2023
Interim report January-September 2023

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all